William Blair analyst Brandon Vazquez has maintained their bullish stance on EW stock, giving a Buy rating today.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Brandon Vazquez has given his Buy rating due to a combination of factors, including Edwards Lifesciences’ deliberate step-up in spending that is intended to capture upside from favorable TAVR guideline changes and potential reimbursement expansion expected in 2026. He views the recent quarter’s strong performance in key franchises such as TAVR and TMTT, along with management’s increased confidence in the 2026 outlook, as reinforcing the company’s long-term growth profile.
In addition, Vazquez highlights an upcoming left atrial appendage closure product that would open a new addressable market where Edwards already has a procedural presence, alongside several near- and medium-term product catalysts such as TAVR share gains from EARLY-TAVR and growing adoption of Evoque, M3, and next-generation Pascal technologies. With the stock having recently pulled back and currently trading at what he views as an attractive multiple relative to expected double-digit EPS growth and possible valuation uplift following policy updates like a revised TAVR NCD, he believes the risk-reward remains favorable, supporting his Buy stance.
In another report released today, Piper Sandler also reiterated a Buy rating on the stock with a $100.00 price target.